Literature DB >> 23695991

The association of insulin resistance with serum osteoprotegerin in obese adolescents.

Joanna Suliburska1, Pawel Bogdanski, Ewa Gajewska, Grazyna Kalmus, Magdalena Sobieska, Wlodzimierz Samborski.   

Abstract

Some data indicate a potential relationship between insulin resistance level and the concentration of osteoprotegerin (OPG) in the body. There have been few studies concerning OPG level and its relationship with insulin resistance and body composition in young people. The aim of this study was to assess serum osteoprotegerin concentration in obese adolescents, and to evaluate its potential association with insulin resistance. Seventy-eight obese adolescents and 20 healthy volunteers aged 12-18 years were recruited in the study. Selected anthropometrical measurements and blood biochemical analyses were performed. Insulin resistance in the participants was evaluated according to the homeostasis model assessment-insulin resistance (HOMA-IR) protocol. Level of OPG was assessed in serum. Obese subjects had significantly higher HOMA-IR indices and OPG levels in serum than the control group. A significant positive correlation between OPG and insulin resistance was found. It was observed that high concentrations of osteoprotegerin are associated with insulin resistance in obese adolescents.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23695991     DOI: 10.1007/s13105-013-0261-8

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  25 in total

1.  Prevalence and trends of severe obesity among US children and adolescents.

Authors:  Joseph A Skelton; Stephen R Cook; Peggy Auinger; Jonathan D Klein; Sarah E Barlow
Journal:  Acad Pediatr       Date:  2009-06-27       Impact factor: 3.107

2.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

Review 3.  RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function.

Authors:  Michael Schoppet; Klaus T Preissner; Lorenz C Hofbauer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-04-01       Impact factor: 8.311

4.  A comparison of osteoprotegerin with adiponectin and high-sensitivity C-reactive protein (hsCRP) as a marker for insulin resistance.

Authors:  Eoin P O'Sullivan; David T Ashley; Colin Davenport; Lakshmi Penugonda; Grainne Kelleher; Niamh Devlin; Rachel Crowley; Paula O'Shea; Amar Agha; Chris J Thompson; Donal J O'Gorman; Diarmuid Smith
Journal:  Metabolism       Date:  2012-07-27       Impact factor: 8.694

5.  Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease.

Authors:  Shuichi Jono; Yuji Ikari; Atsushi Shioi; Katsuhito Mori; Takami Miki; Kazuhiro Hara; Yoshiki Nishizawa
Journal:  Circulation       Date:  2002-09-03       Impact factor: 29.690

6.  Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes.

Authors:  Subhashini Yaturu; Justin Rains; Sushil K Jain
Journal:  Cytokine       Date:  2008-09-11       Impact factor: 3.861

7.  Association between plasma osteoprotegerin concentrations and urinary albumin excretion in Type 2 diabetes.

Authors:  G D Xiang; J H Pu; L S Zhao; H L Sun; J Hou; L Yue
Journal:  Diabet Med       Date:  2009-04       Impact factor: 4.359

Review 8.  Health consequences of obesity.

Authors:  J J Reilly; E Methven; Z C McDowell; B Hacking; D Alexander; L Stewart; C J H Kelnar
Journal:  Arch Dis Child       Date:  2003-09       Impact factor: 3.791

9.  Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study.

Authors:  Jørgen Jeppesen; Tine W Hansen; Susanne Rasmussen; Hans Ibsen; Christian Torp-Pedersen; Sten Madsbad
Journal:  J Am Coll Cardiol       Date:  2007-05-17       Impact factor: 24.094

10.  Serum osteoprotegerin is associated with carotid intima media thickness in women with previous gestational diabetes.

Authors:  Baris Akinci; Tevfik Demir; Aygul Celtik; Mustafa Baris; Serkan Yener; Mehmet Ali Ozcan; Faize Yuksel; Mustafa Secil; Sena Yesil
Journal:  Diabetes Res Clin Pract       Date:  2008-08-21       Impact factor: 5.602

View more
  12 in total

Review 1.  Physiological Changes and Pathological Pain Associated with Sedentary Lifestyle-Induced Body Systems Fat Accumulation and Their Modulation by Physical Exercise.

Authors:  Enrique Verdú; Judit Homs; Pere Boadas-Vaello
Journal:  Int J Environ Res Public Health       Date:  2021-12-17       Impact factor: 3.390

Review 2.  Osteoprotegerin in Cardiometabolic Disorders.

Authors:  C Pérez de Ciriza; A Lawrie; N Varo
Journal:  Int J Endocrinol       Date:  2015-05-11       Impact factor: 3.257

Review 3.  Skeleton and glucose metabolism: a bone-pancreas loop.

Authors:  Maria Felicia Faienza; Vincenza Luce; Annamaria Ventura; Graziana Colaianni; Silvia Colucci; Luciano Cavallo; Maria Grano; Giacomina Brunetti
Journal:  Int J Endocrinol       Date:  2015-03-19       Impact factor: 3.257

4.  Association of osteoprotegerin with impaired glucose regulation and microalbuminuria: the REACTION study.

Authors:  Yixin Niu; Zhen Yang; Xiaoyong Li; Weiwei Zhang; Shuai Lu; Hongmei Zhang; Xueru Chen; Lingfei Zhu; Yin Xing; Guang Ning; Li Qin; Qing Su
Journal:  BMC Endocr Disord       Date:  2015-12-01       Impact factor: 2.763

5.  Association of Osteoprotegerin with Obesity, Insulin Resistance and Non-Alcoholic Fatty Liver Disease in Children.

Authors:  Meltem Erol; Ozlem Bostan Gayret; Hikmet Tekin Nacaroglu; Ozgul Yigit; Oguzhan Zengi; Mehmet Salih Akkurt; Mehmet Tasdemir
Journal:  Iran Red Crescent Med J       Date:  2016-11-01       Impact factor: 0.611

Review 6.  Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease.

Authors:  Lucia Pacifico; Gian Marco Andreoli; Miriam D'Avanzo; Delia De Mitri; Pasquale Pierimarchi
Journal:  World J Gastroenterol       Date:  2018-05-21       Impact factor: 5.742

7.  Cardiovascular risk assessment in osteoporotic patients using osteoprotegerin as a reliable predictive biochemical marker.

Authors:  Carmen G Barbu; Andreea L Arsene; Suzana Florea; Alice Albu; Anca Sirbu; Sorina Martin; Alina C Nicolae; George T A Burcea-Dragomiroiu; Daniela E Popa; Bruno S Velescu; Ion B Dumitrescu; Niculina Mitrea; Doina Draganescu; Dumitru Lupuliasa; Demetrios A Spandidos; Aristides M Tsatsakis; Cristina M Dragoi; Simona Fica
Journal:  Mol Med Rep       Date:  2017-08-28       Impact factor: 2.952

8.  Effects of Sweet Cherry Polyphenols on Enhanced Osteoclastogenesis Associated With Childhood Obesity.

Authors:  Filomena Corbo; Giacomina Brunetti; Pasquale Crupi; Sara Bortolotti; Giuseppina Storlino; Laura Piacente; Alessia Carocci; Alessia Catalano; Gualtiero Milani; Graziana Colaianni; Silvia Colucci; Maria Grano; Carlo Franchini; Maria Lisa Clodoveo; Gabriele D'Amato; Maria Felicia Faienza
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

9.  The risk factor for instability metabolic health and severity.

Authors:  Dhafer A F Al-Koofee; Ali M Omara; Ali B Abulrazzaq; Ruqayah Zaid
Journal:  Mater Today Proc       Date:  2021-12-29

10.  Increased osteoprotegerin level is associated with impaired cardiovagal modulation in type-2 diabetic patients treated with oral antidiabetic drugs.

Authors:  M R Jasmine; Nivedita Nanda; Jayaprakash Sahoo; S Velkumary; G K Pal
Journal:  BMC Cardiovasc Disord       Date:  2020-10-20       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.